Here's Why McKesson Corporation (MCK) Slid in Q2

Janus Henderson Investors, an investment management company, released its second-quarter 2026 investor letter for the "Global Sustainable Equity Fund". A copy of the letter can be downloaded here . Global equities experienced a robust quarter, with the Fund returning 16.17%, outperforming the Index's 13.16% gain and the Peer Group's 12.98% return. An overweight in information technology, particularly AI infrastructure, and underweight positions in energy, materials, and consumer staples were the key drivers. AI significantly contributed to returns, especially among chipmakers. Information technology was the top performer in the quarter with over 30% returns, alongside strong performances from financials and industrials. The portfolio focuses on high-quality companies with competitive advantages and exposure to long-term trends, positioning it to manage evolving investment opportunities and risks. For insights into their key selections for 2026, please review the Strategy's top five holdings.

In its Q2 2026 investor letter, Janus Henderson Global Sustainable Equity Fund highlighted McKesson Corporation (NYSE: MCK ). McKesson Corporation (NYSE:MCK) is a leading US-based healthcare company, that distributes pharmaceuticals, medical supplies and technology solutions. On July 15, 2026, McKesson Corporation (NYSE:MCK) closed at $796.35 per share, reflecting a market capitalization of $93.23 billion. McKesson Corporation (NYSE:MCK) posted a one-month return of 9.60%, while its shares gained 15.82% over the past 52 weeks.

Janus Henderson Global Sustainable Equity Fund stated the following regarding McKesson Corporation (NYSE:MCK) in its Q2 2026 investor update:

"The largest detractors included McKesson Corporation (NYSE:MCK), Spotify and Intercontinental Exchange (ICE). McKesson's share price fell amid a wider derating of drug distributors, driven by GLP-1 cash-pay concerns, a switch into insurers and rising investor concerns around specialty pharmacy exposure ahead of a large wave of loss-of exclusivity events over the next five years. The concern is that lower drug pricing could pressure distributor margins. Our investment thesis remains unchanged. We think McKesson is a leading player in a consolidated market with defensive growth characteristics, scale advantages and durable customer relationships."

McKesson Corporation (NYSE:MCK) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 . According to our database, 73 hedge fund portfolios held McKesson Corporation (NYSE:MCK) at the end of the first quarter, up from 72 in the previous quarter. In the fourth quarter of fiscal 2026, McKesson Corporation's (NYSE:MCK) earnings per diluted share reached $11.69, a 16% increase over the prior year. While we acknowledge the potential of McKesson Corporation (NYSE:MCK) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .

In another article , we covered McKesson Corporation (NYSE:MCK) and shared billionaire Cliff Asness' top healthcare stock picks. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years .

Disclosure: None. This article is originally published at Insider Monkey .

Sinergia Empresarial continuará el seguimiento de esta información sobre here's Why McKesson Corporation (MCK) Slid in Q2 y ampliará la cobertura conforme se confirmen nuevos elementos relevantes para el ecosistema empresarial.